Free Trial

Supply & Vaccines

BOND SUMMARY

The U.S. Tsy space was subjected to some light pressure on the back of headline flow pointing to a Pfizer COVID-19 vaccine being on track for a regulatory review in October. Still T-Notes held to a 0-04 range, last -0-02+ at 139-15+, with yields virtually unchanged across the curve.

  • Supply matters headlined in Australia with a well-received auction of ACGB Nov '24 witnessed, before the longer end was pressured as the AOFM revealed a syndication of the new ACGB Nov '31 line, slated for next week. YM -0.5, XM -3.0.
  • JGBs didn't show any notable reaction to virtually in line with expectation local CPI data, whilethe latest round of BoJ Rinban operations revealed mixed results. Futures last -1, with 7s outperforming in cash trade, and super-long paper a touch weaker on the day.
MNI London Bureau | +44 0203-865-3809 | anthony.barton@marketnews.com
MNI London Bureau | +44 0203-865-3809 | anthony.barton@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.